Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
RESEARCH TOOLSreports
Maravai Lifesciences Holdings (MRVI) Stock Price & Analysis
339 Followers
MRVI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.52 - $13.31
Previous Close$6.99
Volume782.98K
Average Volume (3M)2.09M
Market Cap
$1.76B
Enterprise Value$2.12B
Total Cash (Recent Filing)$561.69M
Total Debt (Recent Filing)$555.72M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 06, 2024EPS Estimate
<$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding251,924,898
10 Day Avg. Volume1,897,577
30 Day Avg. Volume2,094,842
Standard Deviation0.17
R-Squared0.00025
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-14.09
Price to Sales (P/S)3.33
Price to Cash Flow (P/CF)-53.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.74
Enterprise Value/Gross Profit15.13
Enterprise Value/Ebitda151.11
Forecast
1Y Price Target
$11.00Price Target Upside57.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Maravai Lifesciences Holdings News
PremiumCompany Announcements
Maravai Lifesciences Director Resigns for New CFO Role
Bulls Say, Bears Say
Bulls Say
Management ConfidenceFollowing recent completion of capacity expansion and restructuring, management expressed confidence in commercial offerings and operations.
Product PortfolioThe company is encouraged by positive momentum and progress in product portfolio expansions and partnerships.
Revenue Performance1Q revenue of $64mn was above Visible Alpha Consensus Data/GSe of $61mn.
Bears Say
Financial PerformanceAdjusted EBITDA margins came in below expectations due to expenses related to the Flanders facilities and lower volumes.
Financial PerformanceAdjusted EBITDA margins came in below expectations due to expenses related to the Flanders facilities and lower volumes.
Operational CostsAdjusted EBITDA missed our model due to timing of certain operational costs.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MRVI FAQ
What was Maravai Lifesciences Holdings’s price range in the past 12 months?
Maravai Lifesciences Holdings lowest stock price was $4.52 and its highest was $13.31 in the past 12 months.
What is Maravai Lifesciences Holdings’s market cap?
Currently, no data Available
When is Maravai Lifesciences Holdings’s upcoming earnings report date?
Maravai Lifesciences Holdings’s upcoming earnings report date is Aug 06, 2024 which is in 29 days.
How were Maravai Lifesciences Holdings’s earnings last quarter?
Maravai Lifesciences Holdings released its earnings results on May 08, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.026 by $0.006.
Is Maravai Lifesciences Holdings overvalued?
According to Wall Street analysts Maravai Lifesciences Holdings’s price is currently Undervalued.
Does Maravai Lifesciences Holdings pay dividends?
Maravai Lifesciences Holdings does not currently pay dividends.
What is Maravai Lifesciences Holdings’s EPS estimate?
Maravai Lifesciences Holdings’s EPS estimate is <$0.01.
How many shares outstanding does Maravai Lifesciences Holdings have?
Maravai Lifesciences Holdings has 132,830,870 shares outstanding.
What happened to Maravai Lifesciences Holdings’s price movement after its last earnings report?
Maravai Lifesciences Holdings reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.026. Following the earnings report the stock price went up 11.161%.
Which hedge fund is a major shareholder of Maravai Lifesciences Holdings?
Among the largest hedge funds holding Maravai Lifesciences Holdings’s share is Gotham Asset Management LLC. It holds Maravai Lifesciences Holdings’s shares valued at 5M.
---
Maravai Lifesciences Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (57.37% Upside)
$11.00 (57.37% Upside)
Blogger Sentiment
Neutral
MRVI Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 194.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $97.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.65%
12-Months-Change
Fundamentals
Return on Equity
-28.11%
Trailing 12-Months
Asset Growth
-37.61%
Trailing 12-Months
Company Description
Maravai Lifesciences Holdings
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
---
MRVI Company Deck
---
MRVI Earnings Call
Q1 2024
0:00 / 0:00
---
MRVI Revenue Breakdown
77.79% Nucleic Acid Production
22.21% Biologics Safety Testing
---
MRVI Stock 12 Month Forecast
Average Price Target
$11.00
▲(57.37% Upside)
Technical Analysis
BioNTech SE
―
Crispr Therapeutics AG
―
Arcturus Therapeutics
―
Intellia Therapeutics
―
Best Analysts Covering MRVI
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-21.55%
reiterated a buy rating 5 months ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -21.55% per trade.
---